LeddarTech Will Unlock the Value of Raw Data Fusion and Perception at Automotive Tech.AD Berlin (Germany) on April 3-5, 2022
Environmental perception technology for safer autonomous driving with better detection
QUEBEC CITY, March 29, 2022 (GLOBE NEWSWIRE) -- LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce its participation at Automotive Tech.AD Berlin at the Titanic Chaussee Hotel Berlin as an exhibitor and keynote speaker.
April 4-5, 2022: LeddarTech’s LeddarVision™ Demonstrator Space (live and virtual)
Join the LeddarTech team for real-world demonstrations of LeddarVision. The only sensor fusion and perception software using raw data fusion that simplifies complex sensor sets eliminates the dependency on hardware and provides customers the flexibility to quickly scale solutions across vehicle models, delivering greater ADAS and AD performance.
Meet the CTO of LeddarTech, Pierre Olivier, a pioneer in sensing with over 30 years of experience presenting at these events during the conference:
- Sunday, April 3, 2022, 19:45 – 23:00 CET: Icebreaker Session
Topic: The Road to Full Automation - Progress and Challenges
- Monday, April 4, 2022, 10:00 – 10:30 CET: Presentation
Topic: Sensing and Perception Technology – Solutions That Solve Critical Sensing Challenges
Learn about LeddarVision, a raw-data sensor fusion and perception platform that generates a comprehensive 3D RGBD environmental model with multi-sensor support for camera, radar and LiDAR configurations. This software-centric solution delivers superior perception performance exhibited through path planning, free space detection and enhanced object detection, tracking and classification.
Tech.AD Europe fuels you with new ideas, connections and inspiration. This event is directed at advanced engineers and automotive experts from OEMs, Tier 1s, automotive suppliers, solution providers and leading research institutes focusing on AI + machine learning, sensor and perception technologies, software architectures and AV platforms, testing and validation, commercial vehicles and early deployment, connectivity and 5G, infrastructures and smart cities, safety and security and more. Join over 500 of the most influential technical autonomous vehicle experts and executives in Berlin and online! Join LeddarTech either in person or digitally by registering today at https://www.autonomous-driving-berlin.com/.
Founded in 2007, LeddarTech is a comprehensive end-to-end environmental sensing company that enables customers to solve critical sensing, fusion and perception challenges across the entire value chain. LeddarTech provides cost-effective perception solutions scalable from Level 2+ ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types and configurations. LeddarTech also supports LiDAR manufacturers and Tier 1-2 automotive suppliers with key technology building blocks such as LeddarSteer™ digital beam steering and the LiDAR XLRator™, a development solution for automotive-grade solid-state LiDARs based on the LeddarEngine™ and core components from global semiconductor partners. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 100 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference16.5.2022 07:00:00 CEST | Press release
GENEVA, Switzerland May16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 10:30 a.m. EST on Tuesday, May 24, 2022. A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website. About ObsEva ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroi
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease16.5.2022 00:00:00 CEST | Press release
WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. “The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the tre
Cool Company Ltd. – Mandatory Notification of Trade15.5.2022 14:52:24 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Primary insider notification form
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 202213.5.2022 18:00:00 CEST | Press release
Monthly information related to total number of voting rights and shares composing the share capital –April 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut(1) voting rights Total of net (2) voting rights December 31, 202131 018 55332 518 33932 515 839January 31, 202231 018 55332 518 33932 515 839February 28, 202231 018 55332 518 54732 516 047March 31, 202231 018 55332 518 54732 516 047April 30, 202231 018 55332 518 54732 516 047 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on t
Hövding ansöker om avnotering från Nasdaq First North Growth Market13.5.2022 17:45:00 CEST | Pressemelding
Styrelsen för Hövding Sverige AB (publ) (”Hövding”) har beslutat att ansöka om avnotering av Hövdings aktie från Nasdaq First North Growth Market (”First North”). Sista dag för handel på First North kommer att meddelas efter att Hövding erhållit bekräftelse om detta från Nasdaq. Fosielund Holding AB (”Fosielund”) offentliggjorde genom pressmeddelande den 13 januari 2022 ett offentligt budpliktserbjudande till aktieägarna i Hövding (”Erbjudandet”). Fosielund meddelande genom pressmeddelande den 16 februari 2022 att Fosielund (med närstående), efter redovisning av likvid i Erbjudandet, innehade 18 021 741 aktier motsvarande ca 65 procent av aktierna och rösterna. Den 8 april 2022 meddelade Fosielund genom pressmeddelande att de förvärvat en större post aktier i Hövding, varefter Fosielund innehade ca 88,7 procent av aktierna och rösterna samt en avsikt att förvärva ytterligare aktier. Den 4 maj 2022 meddelade Fosielund genom pressmeddelande att de förvärvat ytterligare aktier och att des